262 related articles for article (PubMed ID: 26389833)
1. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.
Nishiwaki S; Imai K; Mizuta S; Kanamori H; Ohashi K; Fukuda T; Onishi Y; Takahashi S; Uchida N; Eto T; Nakamae H; Yujiri T; Mori S; Nagamura-Inoue T; Suzuki R; Atsuta Y; Tanaka J
Bone Marrow Transplant; 2016 Jan; 51(1):43-50. PubMed ID: 26389833
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
Konuma T; Mizuno S; Kondo T; Yamaguchi H; Fukuda T; Uchida N; Najima Y; Kanamori H; Ota S; Nakamae H; Nakamae M; Mizuno I; Sugita J; Onishi Y; Yokota A; Takahashi S; Kanda Y; Ichinohe T; Atsuta Y; Yano S;
Ann Hematol; 2018 Nov; 97(11):2173-2183. PubMed ID: 29978286
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
Nishiwaki S; Akahoshi Y; Mizuta S; Shinohara A; Hirabayashi S; Noguchi Y; Fukuda T; Uchida N; Tanaka M; Onizuka M; Ozawa Y; Ota S; Shiratori S; Onishi Y; Kanda Y; Sawa M; Tanaka J; Atsuta Y; Kako S
Blood Adv; 2021 Jan; 5(2):584-592. PubMed ID: 33496752
[TBL] [Abstract][Full Text] [Related]
7. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
9. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
10. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia.
Nakasone H; Kako S; Mori T; Takahashi S; Onizuka M; Fujiwara SI; Sakura T; Sakaida E; Yokota A; Aotsuka N; Hagihara M; Tsukada N; Hatta Y; Usuki K; Watanabe R; Gotoh M; Fujisawa S; Yano S; Kanamori H; Okamoto S; Kanda Y
Bone Marrow Transplant; 2021 Jun; 56(6):1402-1412. PubMed ID: 33420396
[TBL] [Abstract][Full Text] [Related]
11. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.
Akahoshi Y; Nishiwaki S; Arai Y; Harada K; Najima Y; Kanda Y; Shono K; Ota S; Fukuda T; Uchida N; Shiratori S; Tanaka M; Tanaka J; Atsuta Y; Kako S
Bone Marrow Transplant; 2020 Jul; 55(7):1317-1325. PubMed ID: 32447350
[TBL] [Abstract][Full Text] [Related]
14. Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.
Takashima S; Miyamoto T; Kamimura T; Yoshimoto G; Yoshida S; Henzan H; Takase K; Kato K; Ito Y; Ohno Y; Nagafuji K; Eto T; Techima T; Akashi K
Int J Hematol; 2015 Dec; 102(6):689-96. PubMed ID: 26475283
[TBL] [Abstract][Full Text] [Related]
15. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
Bachanova V; Marks DI; Zhang MJ; Wang H; de Lima M; Aljurf MD; Arellano M; Artz AS; Bacher U; Cahn JY; Chen YB; Copelan EA; Drobyski WR; Gale RP; Greer JP; Gupta V; Hale GA; Kebriaei P; Lazarus HM; Lewis ID; Lewis VA; Liesveld JL; Litzow MR; Loren AW; Miller AM; Norkin M; Oran B; Pidala J; Rowe JM; Savani BN; Saber W; Vij R; Waller EK; Wiernik PH; Weisdorf DJ
Leukemia; 2014 Mar; 28(3):658-65. PubMed ID: 23989431
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
18. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
20. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Nishiwaki S; Miyamura K; Kato C; Terakura S; Ohashi K; Sakamaki H; Nakao S; Harigae H; Kodera Y
Anticancer Res; 2010 Jun; 30(6):2415-8. PubMed ID: 20651401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
